IP Library › Granted Patent US 12,274,883
Granted Patent B2
US 12,274,883 · App. 18/091,954 · Granted Apr 15, 2025

Methods and systems for electroporation

Inventor: Samuel J. Asirvatham (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
A61N1/36507A61B5/283A61B5/316A61N1/056A61B2018/00351A61B2018/00613A61B2018/00839A61B18/12A61N1/327
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,274,883
App. No.
18/091,954
Granted
Apr 15, 2025
Kind
B2
Abstract

This document describes methods and materials for improving the delivery of electroporation. For example, this document describes methods and devices for delivering electroporation while mitigating risks of ventricular fibrillation.

Claims (96)

1. A method of triggering electroporation, the method comprising:

inserting a lead in or around a heart of a patient, the lead comprising a first electrode, a second electrode, and a third electrode that are both sensing and delivering electrodes;

delivering electroporation stimulation to the heart below a threshold during a cardiac cycle of the patient;

measuring a first electrocardiogram between the first and second electrodes of the lead;

measuring a second electrocardiogram between the first and third electrodes of the lead;

comparing the first and second electrocardiograms;

identifying signals common to the first and second electrocardiograms;

removing the signals common to the first and second electrocardiograms, thereby creating a modified electrocardiogram;

determining whether the modified electrocardiogram comprises a cardiac signal;

identifying a vulnerable period in the cardiac cycle by detecting a signal summation in the cardiac signal; and

in response to: i) determining that the modified electrocardiogram comprises the cardiac signal, and ii) identifying the vulnerable period of the cardiac cycle, delivering electroporation stimulation above the threshold to the heart during the cardiac cycle except during the vulnerable period by using at least one of the first, second, and third electrodes after the cardiac signal is determined,

wherein the threshold comprises a voltage of about 10 microvolts to about 100 microvolts.

2. The method of claim 1 , wherein a distance between the first electrode and the third electrode is greater than a distance between the first electrode and the second electrode.

3. The method of claim 1 , wherein the first and second electrodes are located linearly along the lead.

4. The method of claim 1 , wherein the first and third electrodes are located linearly along the lead.

5. The method of claim 1 , wherein a filter is used to remove the signals common to the first and second electrocardiograms.

6. The method of claim 5 , wherein the filter is a common mode rejection filter.

7. The method of claim 1 , wherein the delivering electroporation stimulation to the heart below the threshold during the cardiac cycle of the patient comprises:

delivering a first set of stimulation pulses for the cardiac cycle, wherein the first set of stimulation pulses has a first intensity below the threshold; and

delivering a third set of stimulation pulses for the cardiac cycle, wherein the third set of stimulation pulses has a third intensity between the first intensity and the threshold; and

wherein the delivering electroporation stimulation to the heart above the threshold during the cardiac cycle of the patient comprises:

delivering a second set of stimulation pulses for the cardiac cycle, wherein the second set of stimulation pulses has a second intensity above the threshold; and

delivering a fourth set of stimulation pulses for the cardiac cycle when the signal summation is not detected, wherein the fourth set of stimulation pulses has a fourth intensity above the threshold.

8. The method of claim 7 , wherein the signal summation is indicative of the vulnerable period of the cardiac cycle.

9. The method of claim 1 , wherein delivering electroporation stimulation above the threshold to the heart during the cardiac cycle except during the vulnerable period decreases a risk of generating an unwanted arrhythmia or an unwanted ventricular fibrillation.

10. The method of claim 1 , wherein delivering electroporation stimulation above the threshold to the heart during the cardiac cycle except during the vulnerable period comprises delivering supra-threshold pulses to the heart, the supra-threshold pulses comprising a pulse width of about 100 nanoseconds (ns) to about 3 milliseconds (ms) and an amplitude of about 1 volt to about 4 kilovolts.

11. A device for delivering electroporation, the device comprising:

a lead comprising a first electrode, a second electrode, and a third electrode that are both sensing and delivering electrodes;

a memory that is capable of storing computer executable instructions; and

a processor that is configured to facilitate execution of the executable instructions stored in memory, wherein the instructions configure the processor to:

deliver electroporation stimulation to a heart of a patient below a threshold during a cardiac cycle;

measure cardiac signals from at least one of the first, second, and third electrodes on the lead, wherein the measuring of cardiac signals comprises:

measuring a first electrocardiogram between the first and second electrodes;

measuring a second electrocardiogram between the first and third electrodes;

comparing the first and second electrocardiograms;

identifying signals common to the first and second electrocardiograms;

removing signals common to the first and second electrocardiograms, thereby creating a modified electrocardiogram; and

determining whether the modified electrocardiogram comprises a cardiac signal;

identify a vulnerable period in the cardiac cycle by detecting a signal summation in the cardiac signal; and

in response to: (i) determining that the modified electrocardiogram comprises the cardiac signal, and (ii) identifying the vulnerable period of the cardiac cycle, deliver electroporation stimulation above the threshold to the heart during the cardiac cycle except during the vulnerable period by using at least one of the first, second, and third electrodes after the cardiac signal is determined,

wherein the delivery of electroporation stimulation to the heart below the threshold during the cardiac cycle of the patient comprises:

delivering a first set of stimulation pulses for the cardiac cycle, wherein the first set of stimulation pulses has a first intensity below the threshold; and

delivering a third set of stimulation pulses for the cardiac cycle, wherein the third set of stimulation pulses has a third intensity between the first intensity and the threshold, and

wherein the delivery of electroporation stimulation to the heart above the threshold during the cardiac cycle of the patient comprises:

delivering a second set of stimulation pulses for the cardiac cycle, wherein the second set of stimulation pulses has a second intensity above the threshold; and

delivering a fourth set of stimulation pulses for the cardiac cycle when the signal summation is not detected, wherein the fourth set of stimulation pulses has a fourth intensity above the threshold, and wherein the threshold comprises a voltage of about 10 microvolts to about 100 microvolts.

12. The device of claim 11 , wherein the electrodes are positioned linearly along a length of the lead, and wherein a distance between the first electrode and the third electrode is greater than a distance between the first electrode and the second electrode.

13. The device of claim 11 , wherein a filter is used to remove the signals common to the first and second electrocardiograms.

14. The device of claim 13 , wherein the filter is a common mode rejection filter.

15. The device of claim 11 , wherein delivering electroporation stimulation above the threshold to the heart during the cardiac cycle except during the vulnerable period decreases a risk of generating an unwanted arrhythmia or an unwanted ventricular fibrillation.

16. The device of claim 11 , wherein delivering electroporation stimulation above the threshold to the heart during the cardiac cycle except during the vulnerable period comprises delivering supra-threshold pulses to the heart, the supra-threshold pulses comprising a pulse width of about 100 ns to about 3 ms and an amplitude of about 1 volt to about 4 kilovolts.

17. A device for delivering electroporation, the device comprising:

a lead comprising a first electrode, a second electrode, and a third electrode that are both sensing and delivering electrodes;

a memory that is capable of storing computer executable instructions; and

a processor that is configured to facilitate execution of the executable instructions stored in memory, wherein the instructions configure the processor to:

deliver electroporation stimulation to a heart of a patient below a threshold during a cardiac cycle;

measure cardiac signals from at least one of the first, second, and third electrodes on the lead, wherein the measuring of cardiac signals comprises:

measuring a first electrocardiogram between the first and second electrodes;

measuring a second electrocardiogram between the first and third electrodes;

comparing the first and second electrocardiograms;

identifying signals common to the first and second electrocardiograms;

removing signals common to the first and second electrocardiograms, thereby creating a modified electrocardiogram; and

determining whether the modified electrocardiogram comprises a cardiac signal;

identify a vulnerable period in the cardiac cycle by detecting a signal summation in the cardiac signal; and

in response to: (i) determining that the modified electrocardiogram comprises the cardiac signal, and (ii) identifying the vulnerable period of the cardiac cycle, deliver electroporation stimulation above the threshold to the heart during the cardiac cycle except during the vulnerable period by using at least one of the first, second, and third electrodes after the cardiac signal is determined,

wherein delivering electroporation stimulation above the threshold to the heart during the cardiac cycle except during the vulnerable period decreases a risk of generating an unwanted arrhythmia or an unwanted ventricular fibrillation.

18. A device for delivering electroporation, the device comprising:

a lead comprising a first electrode, a second electrode, and a third electrode that are both sensing and delivering electrodes;

a memory that is capable of storing computer executable instructions; and

a processor that is configured to facilitate execution of the executable instructions stored in memory, wherein the instructions configure the processor to:

deliver electroporation stimulation to a heart of a patient below a threshold during a cardiac cycle;

measure cardiac signals from at least one of the first, second, and third electrodes on the lead, wherein the measuring of cardiac signals comprises:

measuring a first electrocardiogram between the first and second electrodes;

measuring a second electrocardiogram between the first and third electrodes;

comparing the first and second electrocardiograms;

identifying signals common to the first and second electrocardiograms;

removing signals common to the first and second electrocardiograms, thereby creating a modified electrocardiogram; and

determining whether the modified electrocardiogram comprises a cardiac signal;

identify a vulnerable period in the cardiac cycle by detecting a signal summation in the cardiac signal; and

in response to: (i) determining that the modified electrocardiogram comprises the cardiac signal, and (ii) identifying the vulnerable period of the cardiac cycle, deliver electroporation stimulation above the threshold to the heart during the cardiac cycle except during the vulnerable period by using at least one of the first, second, and third electrodes after the cardiac signal is determined,

wherein delivering electroporation stimulation above the threshold to the heart during the cardiac cycle except during the vulnerable period comprises delivering supra-threshold pulses to the heart, the supra-threshold pulses comprising a pulse width of about 100 ns to about 3 ms and an amplitude of about 1 volt to about 4 kilovolts.

19. A device for delivering electroporation, the device comprising:

a lead comprising a first electrode, a second electrode, and a third electrode that are both sensing and delivering electrodes;

a memory that is capable of storing computer executable instructions; and

a processor that is configured to facilitate execution of the executable instructions stored in memory, wherein the instructions configure the processor to:

deliver electroporation stimulation to a heart of a patient below a threshold during a cardiac cycle;

measure cardiac signals from at least one of the first, second, and third electrodes on the lead, wherein the measuring of cardiac signals comprises:

measuring a first electrocardiogram between the first and second electrodes;

measuring a second electrocardiogram between the first and third electrodes;

comparing the first and second electrocardiograms;

identifying signals common to the first and second electrocardiograms;

removing signals common to the first and second electrocardiograms, thereby creating a modified electrocardiogram; and

determining whether the modified electrocardiogram comprises a cardiac signal;

identify a vulnerable period in the cardiac cycle by detecting a signal summation in the cardiac signal; and

in response to: (i) determining that the modified electrocardiogram comprises the cardiac signal, and (ii) identifying the vulnerable period of the cardiac cycle, deliver electroporation stimulation above the threshold to the heart during the cardiac cycle except during the vulnerable period by using at least one of the first, second, and third electrodes after the cardiac signal is determined,

wherein the threshold comprises a voltage of about 10 microvolts to about 100 microvolts.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2023
From: ASIRVATHAM, SAMUEL J.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 062375/0263 →
Continuity (3)
Division 16763712
Provisional Application 62597007 · Dec 11, 2017
Related Publication 20230149718A1 · May 18, 2023
References Cited (83)
US 4166113A · Norton et al. · 1979 [cited by applicant]
US 4819751A · Shimada et al. · 1989 [cited by applicant]
US 5640967A · Fine · 1997 [cited by examiner]
US 5860974A · Abele · 1999 [cited by applicant]
US 6023638A · Swanson · 2000 [cited by applicant]
US 6086582A · Altman et al. · 2000 [cited by applicant]
US 7190997B1 · Darvish et al. · 2007 [cited by applicant]
US 7736346B2 · Miller et al. · 2010 [cited by applicant]
US 8036741B2 · Jahns et al. · 2011 [cited by applicant]
US 11541241B2 · Asirvatham · 2023 [cited by applicant]
US 11969197B2 · DeSimone et al. · 2024 [cited by applicant]
US 12076070B2 · Forsyth · 2024 [cited by examiner]
US 20010041890A1 · Hassett et al. · 2001 [cited by applicant]
US 20020151812A1 · Scheiner et al. · 2002 [cited by applicant]
US 20090099560A1 · Rioux et al. · 2009 [cited by applicant]
US 20110144028A1 · Sharma · 2011 [cited by applicant]
US 20120143099A1 · Daniels et al. · 2012 [cited by applicant]
US 20130066315A1 · Subramaniam et al. · 2013 [cited by applicant]
US 20130253616A1 · Libbus et al. · 2013 [cited by applicant]
US 20140081111A1 · Tun et al. · 2014 [cited by applicant]
US 20150132409A1 · Stein et al. · 2015 [cited by applicant]
US 20160051324A1 · Stewart et al. · 2016 [cited by applicant]
US 20160058504A1 · Davies et al. · 2016 [cited by applicant]
US 20160113586A1 · Hemming · 2016 [cited by examiner]
US 20160113709A1 · Maor · 2016 [cited by applicant]
US 20160249978A1 · Lee et al. · 2016 [cited by applicant]
US 20160270845A1 · Benscoter et al. · 2016 [cited by applicant]
US 20160310211A1 · Long · 2016 [cited by applicant]
US 20170035499A1 · Stewart et al. · 2017 [cited by examiner]
US 20170042614A1 · Salahieh et al. · 2017 [cited by applicant]
US 20170065339A1 · Mickelsen · 2017 [cited by applicant]
US 20170105793A1 · Cao et al. · 2017 [cited by applicant]
US 20170189097A1 · Viswanathan · 2017 [cited by examiner]
US 20170340888A1 · Callas et al. · 2017 [cited by applicant]
US 20180085159A1 · Sulkin et al. · 2018 [cited by applicant]
US 20180214196A1 · Eum et al. · 2018 [cited by applicant]
US 20190105057A1 · Radl et al. · 2019 [cited by applicant]
US 20200205890A1 · Harlev et al. · 2020 [cited by applicant]
US 20200298008A1 · Asirvatham · 2020 [cited by applicant]
US 20200305946A1 · DeSimone et al. · 2020 [cited by applicant]
CA 2158051 · 1994 [cited by applicant]
WO WO2011159641 · 2011 [cited by applicant]
WO WO2014143898 · 2014 [cited by applicant]
WO WO2014195933 · 2014 [cited by applicant]
WO WO2017062753 · 2017 [cited by applicant]
WO WO2017074920 · 2017 [cited by applicant]
Boyden et al., “Cardiac Purkinje fibers and arrhythmias; The GK Moe Award Lecture 2015,” Hearth Rhythm, May 2016, 13(5):1172-1181. [cited by applicant]
Damiano Jr. et al., “The effect of chemical ablation of the endocardium on ventricular fibrillation threshold,” Circulation, Sep. 1986, 74(3):645-652. [cited by applicant]
DeSimone et al., “Novel balloon catheter device with pacing, ablating, electroporation, and drug-eluting capabilities for atrial fibrillation treatment—preliminary efficacy and safety studies in a canine model,” Transl.… [cited by applicant]
Evans Jr. et al., “Predictors of in-hospital mortality after DC catheter ablation of atrioventricular junction. Results of a prospective, international, multicenter study,” Circulation, Nov. 1991, 84(5):1924-1937. [cited by applicant]
Frühling et al., “Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results,” Eur. J. Surg. Oncology… [cited by applicant]
Haïssaguerre et al., “Mapping and ablation of idiopathic ventricular fibrillation,” Circulation, Aug. 2002, 106(8):962-967. [cited by applicant]
Haïssaguerre et al., “Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation,” Lancet, Feb. 2002, 359(9307):677-678. [cited by applicant]
Hou et al., “Determination of ventricular vulnerable period and ventricular fibrillation threshold by use of T-wave shocks in patients undergoing implantation of cardioverter/defibrillators,” Circulation, Nov. 1, 1995, … [cited by applicant]
Hwang et al., “Upper limit of vulnerability reliably predicts the defibrillation threshold in humans,” Circulation, Nov. 1994, 90(5):2308-2314. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2018/064914 dated Jun. 25, 2020, 9 pages. [cited by applicant]
International Search Report & Written Opinion in International Application No. PCT/US2018/064914 dated Feb. 27, 2019, 15 pages. [cited by applicant]
Knecht et al., “Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study,” J. Am. Coll. Cardiology, Aug. 4, 2009, 54(6):522-528. [cited by applicant]
Lemery et al., “Low energy direct current ablation in patients with the Wolff-Parkinson-White syndrome: clinical outcome according to accessory pathway location,” Pacing Clin. Electrophysiology, Nov. 1991, 14(11 Pt 2):1… [cited by applicant]
Livia et al., “Electroporative Elimination of Purkinje Fibers Reduces Vulnerability to Ventricular Fibrillation,” Presented at Heart Rhythm Society, May 11-12, 2017, 1 page. [cited by applicant]
Lopera et al., “Identification and ablation of three types of ventricular tachycardia involving the his-purkinje system in patients with heart disease,” J. Cardiovasc. Electrophysiol., 2004, 15(1):52-58. [cited by applicant]
Minners et al., “Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection,” Cardiovasc. Research, Jul. 2000, 47(1):68-73. [cited by applicant]
Neven et al., “Epicardial linear electroporation ablation and lesion size,” Heart Rhythm, Aug. 2014, 11(8):1465-1470. [cited by applicant]
Nogami et al., “Mapping and ablation of idiopathic ventricular fibrillation from the Purkinje system,” Heart Rhythm, 2005, 2(6):646-649. [cited by applicant]
Odening et al., “Electro-Mechanical Remodeling in Transgenig Short QT Syndrome Rabbits,” Poster C-PO04-01:S327, Heart Rhythm Society in May 11-12, 2017, 1 page. [cited by applicant]
O'Nénáin et al., “Catheter ablation by low energy DC shocks for successful management of atrial flutter,” Br. Heart Journal, Jan. 1992, 67(1):67-71. [cited by applicant]
Santoro et al., “Ventricular fibrillation triggered by PVCs from papillary muscles: clinical features and ablation,” J. Cardiovasc. Electrophysiology, Nov. 2014, 25(11):1158-1164. [cited by applicant]
Sutter et al., “Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series,” Radiology, Sep. … [cited by applicant]
Swerdlow et al., “Comparative reproducibility of defibrillation threshold and upper limit of vulnerability,” Pacing Clin. Electrophysiology, Dec. 1996, 19(12 Pt 1):2103-2111. [cited by applicant]
Valerio et al., “Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer,” J. Urology, Mar. 2017, 197(3 Pt 1):647-654. [cited by applicant]
van Driel et al., “Pulmonary vein stenosis after catheter ablation: electroporation versus radiofrequency,” Circ. Arrhythm. Electrophysiology, Aug. 2014, 7(4):734-738. [cited by applicant]
Vogel et al., “Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study,” Ann. Surg. Oncology, Sep. 2017, 24(9):2734-2743. [cited by applicant]
Witt et al., “Electroporative Myocardial Ablation Utilizing a Non-contact, Virtual Electrode: Proof of Concept in Ex-vivo and In-vivo Canine Hearts,” Poster, Presented at Heart Rhythm Society, May 11-12, 2017, 1 page. [cited by applicant]
Witt et al., “Electroporative Myocardial Ablation Utilizing a Non-contact, Virtual Electrode: Proof of Concept in Ex-vivo and In-vivo Canine Hearts,” Presented at Heart Rhythm Society in May 11-12, 2017, 14(5):S327-S417. [cited by applicant]
Wittkampf et al., “Myocardial lesion depth with circular electroporation ablation,” Circ. Arrhythm. Electrophysiology, Jun. 1, 2012, 5(3):581-586. [cited by applicant]
Yeh et al., “Simplified Method for Concentration of Mitochondrial Membrane Protein Complexes,” Electrophoresis, Jun. 2010, 31(12):1934-1936. [cited by applicant]
U.S. Appl. No. 16/754,935, filed Apr. 9, 2020, Christopher V. DeSimone, Published as U.S. Patent Application Publication No. 2020/0305946. [cited by applicant]
Chen et al., “Comparison of the defibrillation threshold and the upper limit of ventricular vulnerability,” Circulation, May 1986, 73(5):1022-1028. [cited by applicant]
Kleinhaus et al., “The effects on canine cardiac Purkinje fibers of Chrysaora quinquecirrha (sea nettle) toxin,” Toxicon, Jul. 1973, 11(4):341-349. [cited by applicant]
Livia et al., “Abstract #: C-PO04-139: Electroporative Elimination of Purkinje Fibers Reduces Vulnerability to Ventricular Fibrillation,” Heart Rhythm, May 2017, 14(5):S327-S417. [cited by applicant]
Livia et al., “Elimination of Purkinje Fibers by Electroporation Reduces Ventricular Fibrillation Vulnerability,” J. Am. Heart Assoc., Aug. 2018, 7(15):e009070, 9 pages. [cited by applicant]
McLeod et al., “Delayed ischemic preconditioning activates nuclear-encoded electron-transfer chain gene expression in parallel with enhanced postanoxic mitochondrial respiratory recovery,” Circulation, Aug. 2004, 110:53… [cited by applicant]
Spiro et al., “Use of left ventricular support devices during acute coronary syndrome and percutaneous coronary intervention,” Curr. Cardiol. Rep., Dec. 2014, 16(12):544. [cited by applicant]